Tru Datt: Ride the dip with these smart ASX stocks

June can be a rough ride for the market - which offers a chance to snap up tomorrow’s blue-chip stocks at bargain prices, says investment guru Emanuel Datt.

When the going seems a little rough, it can be time to ride. Picture: Getty Images

Welcome to Tru Datt, a Stockhead exclusive featuring the insights and opportunities as per Emanuel Datt – founder and chief investment officer at Datt Capital – a Melbourne-based investment manager focused on identifying growth and special situation investments.

---

Investors would do well to take advantage of annual market volatility in June and buy on the dip, says Emanuel Datt.

“Australian markets typically dip in June as investor rationalise their portfolios by selling stocks in a capital loss position, to harvest tax losses to offset against other forms of capital appreciation crystalised during the year,” he said.

“This has the effect of potentially reducing their taxable income or gains.

“As tax loss season is a very well-known phenomenon in Australian markets, we believe there is a very high probability of a positive July and are positioning our portfolios accordingly.”

---

For the latest investment news, sign up here for free Stockhead daily newsletters

---

In its small company fund, Datt Capital is looking to deploy a large cash holding and take advantage of good opportunities to buy the “blue-chip” companies of tomorrow at bargain prices.

Datt said that instead of being scared off by this predictable volatility investors should follow suit and use it as a time to find good companies at low prices across all sectors of the market, not just small caps.

“This is a time of year that all investors should plan for if they can,” he said.

After all, the S&P/ASX 200 (XJO), Australia’s leading share market index, has been positive around 9 per cent this financial year, Datt said.

Although market expectations are mixed around more rate hikes this year, Datt does not expect this to influence market direction.

“Interest rates have been at normalised levels for some time now, so potential hikes will not affect the market materially in our opinion and present CPI numbers are in line with our expectations,” he said.

“Our longer-term market outlook is flat with an upward bias and higher volatility,” Datt said.

---

MORE FROM STOCKHEAD: Five stocks with vital news looming | Discovery Capital’s five top picks | How to avoid greenwashing scandals

---

Three ASX small caps to watch

Datt reckons these three companies are among the ASX stocks investors should have on their radars.

JUPITER MINES (ASX:JMS)

Jupiter Mines is a South African manganese producer which owns 50 per cent of the world-class Tsipi mine.

“We anticipate improved earnings from sustainably stronger manganese prices over time,” Datt said. “It’s likely that the manganese market will remain supply constrained for at least the next 12 months.

“The stock trades at a modest EBITDA multiple and we anticipate potential upside both from the strong earnings growth and multiple expansion as global manganese stocks reduce.”

WA1 RESOURCES (ASX:WA1)

WA1 Resource, a junior miner, discovered the world class Luni niobium deposit in Western Australia; the first major niobium find in almost 50 years, Datt says.

“Niobium is a high value, critical metal that is very important for strategic applications including specialist steels and battery technology,” he said.

“It is listed as a top three most critical metal by all major Western jurisdictions, including the US, UK and EU, due to its extreme scarcity.

“Luni represents the only major niobium deposit located in a Western nation, so represents an extremely valuable strategic asset.

“The maiden MRE expected to be released imminently with further information on metallurgical recoveries and steps to commercialisation to follow.”

---

Visit Stockhead, where ASX small caps are big deals

---

CLARITY PHARMACEUTICALS (ASX:CU6)

Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for better diagnostics and treatments in oncology.

“The company has a number of novel products currently going through a range of clinical trials, each which could materially augment the value proposition in the case of success,” Datt said.

“We are expecting strong new flow from the company over the first half of FY25.”

This content first appeared on stockhead.com.au

The views, information, or opinions expressed in this article are solely those of the interviewees and do not represent the views of Stockhead. Stockhead does not provide, endorse or otherwise assume responsibility for any financial product advice contained in this article.

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox. Click here

Originally published as Tru Datt: Ride the dip with these smart ASX stocks